Equillium Inc. is a clinical-stage biotechnology enterprise that discovers, develops, and commercializes innovative therapeutic products designed to treat severe autoimmune, inflammatory, and immuno-oncology diseases. Its research pipeline harnesses advanced immunobiology to address high unmet medical needs across challenging immunological conditions.